Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.47 |
| ▸ | MMP7 | P09237 | 3/20 | 0.46 |
| ▸ | MMP12 | P39900 | 3/20 | 0.46 |
| ▸ | MMP3 | P08254 | 2/20 | 0.46 |
| ▸ | MMP10 | P09238 | 2/20 | 0.46 |
| ▸ | MMP8 | P22894 | 2/20 | 0.46 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.45 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4938421 | 0.95 | USP30 (0.54) | USP30HDAC4HDAC6GABRA5PARP1 | |
| SCHEMBL3638888 | 0.95 | USP30 (0.54) | USP30HDAC4HDAC6GABRA5PARP1 | |
| SCHEMBL7756336 | 0.90 | HDAC4 (0.51) | USP30HDAC4HDAC6MMP7MMP12 | |
| SCHEMBL28784362 | 0.85 | AURKA (0.41) | — | |
| SCHEMBL4938120 | 0.83 | USP30 (0.44) | USP30HDAC4HDAC6PARP1MMP7 | |
| SCHEMBL3727248 | 0.83 | BRD4 (0.49) | USP30 | |
| SCHEMBL3727246 | 0.83 | BRD4 (0.49) | USP30 | |
| SCHEMBL18960797 | 0.82 | CYP2C9 (0.44) | USP30HDAC4HDAC6GABRA5PARP1 | |
| SCHEMBL4946817 | 0.81 | USP30 (0.57) | USP30HDAC4HDAC6GABRA5PARP1 | |
| SCHEMBL3724794 | 0.80 | USP30 (0.56) | USP30HDAC4HDAC6PARP1DGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155719-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008147945-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | USP30 2123/4885HDAC4 652/4885HDAC6 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.